Mylan – Recall of daptomycin injection

- On July 7, 2020, Mylan announced a voluntary, user level recall of one lot of daptomycin for injection due to the presence of particulate matter in one single-dose vial.
- The recalled lot was distributed nationwide between April 2020 and May 2020:

Product Description	NDC#	Lot# (Expiration Date)
Daptomycin for Injection, 500 mg/vial, 20 mL vial	67457-813-50	7605112 (10/2021)

- Daptomycin for injection is an injectable antibacterial indicated for the treatment of complicated skin and skin structure infections and *Staphylococcus aureus* bloodstream infections (bacteremia) in adult patients.
- Intravenous administration of a solution containing visible particulates could lead to serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.
- To date, Mylan has not received any reports of adverse events related to this recall.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Contact Mylan Customer Relations by phone at **1-800-796-9526** or by email at **customer.service@mylan.com** for further information regarding this recall.